Enlivex Ltd. SEC filings ENLV

Enlivex Ltd. has 419 filings in SEC EDGAR's recent list, going back to Feb 7, 2014. Its latest annual report, Form 20-F, was filed on Mar 25, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Nov 2, 2026. The company's fiscal year ends on December 31.

Enlivex Ltd. SEC filings
Form Description Filed Period
20-F Annual report (foreign issuer) Mar 25, 2026 Dec 31, 2025
20-F Annual report (foreign issuer) Apr 30, 2025 Dec 31, 2024
20-F Annual report (foreign issuer) Apr 30, 2024 Dec 31, 2023
20-F Annual report (foreign issuer) Apr 10, 2023 Dec 31, 2022
20-F Annual report (foreign issuer) Apr 29, 2022 Dec 31, 2021
20-F Annual report (foreign issuer) Apr 30, 2021 Dec 31, 2020
20-F Annual report (foreign issuer) Apr 30, 2020 Dec 31, 2019
20-F/A Amended annual report (foreign issuer) Jan 31, 2020 Dec 31, 2018
20-F/A Amended annual report (foreign issuer) Jan 23, 2020 Dec 31, 2018
20-F Annual report (foreign issuer) Apr 30, 2019 Dec 31, 2018
20-F Annual report (foreign issuer) Apr 23, 2018 Dec 31, 2017
20-F Annual report (foreign issuer) Feb 24, 2017 Dec 31, 2016
20-F Annual report (foreign issuer) Mar 29, 2016 Dec 31, 2015
20-F Annual report (foreign issuer) Mar 31, 2015 Dec 31, 2014

Showing 14 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Finance Services (SIC 6199)
Listed as
ENLV (Nasdaq)
Fiscal year ends
December 31
Incorporated in
Israel
Headquarters
Tel Aviv
SEC filer status
Non-accelerated filer
SEC CIK
1596812
Former names
Enlivex Therapeutics Ltd. (until Feb 10, 2026); Bioblast Pharma Ltd. (until Mar 18, 2019); BIO BLAST PHARMA LTD. (until Sep 12, 2016)

Other Finance Services companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.